vs
PIPER SANDLER COMPANIES（PIPR）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是PIPER SANDLER COMPANIES的1.2倍（$772.1M vs $667.0M），PIPER SANDLER COMPANIES净利率更高（17.1% vs 12.7%，领先4.3%），PIPER SANDLER COMPANIES同比增速更快（37.4% vs 5.9%），过去两年PIPER SANDLER COMPANIES的营收复合增速更高（39.2% vs 9.0%）
Piper Sandler是一家美国跨国投资银行及金融服务提供商，核心业务覆盖并购重组、财务重整、公开募股、公共财政、机构经纪、投资管理、证券研究等领域，通过旗下核心子公司Piper Sandler & Co.为企业、机构投资者及公共组织提供专业金融服务。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
PIPR vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.2倍
$667.0M
营收增速更快
PIPR
高出31.6%
5.9%
净利率更高
PIPR
高出4.3%
12.7%
两年增速更快
PIPR
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $667.0M | $772.1M |
| 净利润 | $114.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 28.3% | 14.5% |
| 净利率 | 17.1% | 12.7% |
| 营收同比 | 37.4% | 5.9% |
| 净利润同比 | 65.0% | 3.9% |
| 每股收益（稀释后） | $6.41 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PIPRRVTY
| Q4 25 | $667.0M | $772.1M | ||
| Q3 25 | $480.1M | $698.9M | ||
| Q2 25 | $398.6M | $720.3M | ||
| Q1 25 | $358.6M | $664.8M | ||
| Q4 24 | $485.4M | $729.4M | ||
| Q3 24 | $360.9M | $684.0M | ||
| Q2 24 | $340.8M | $691.7M | ||
| Q1 24 | $344.4M | $649.9M |
净利润PIPRRVTY
| Q4 25 | $114.0M | $98.4M | ||
| Q3 25 | $60.3M | $46.7M | ||
| Q2 25 | $42.2M | $53.9M | ||
| Q1 25 | $64.9M | $42.2M | ||
| Q4 24 | $69.1M | $94.6M | ||
| Q3 24 | $34.8M | $94.4M | ||
| Q2 24 | $34.8M | $55.4M | ||
| Q1 24 | $42.5M | $26.0M |
毛利率PIPRRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率PIPRRVTY
| Q4 25 | 28.3% | 14.5% | ||
| Q3 25 | 22.4% | 11.7% | ||
| Q2 25 | 12.3% | 12.6% | ||
| Q1 25 | 8.2% | 10.9% | ||
| Q4 24 | 16.9% | 16.3% | ||
| Q3 24 | 15.4% | 14.3% | ||
| Q2 24 | 8.3% | 12.4% | ||
| Q1 24 | 15.2% | 6.8% |
净利率PIPRRVTY
| Q4 25 | 17.1% | 12.7% | ||
| Q3 25 | 12.6% | 6.7% | ||
| Q2 25 | 10.6% | 7.5% | ||
| Q1 25 | 18.1% | 6.4% | ||
| Q4 24 | 14.2% | 13.0% | ||
| Q3 24 | 9.6% | 13.8% | ||
| Q2 24 | 10.2% | 8.0% | ||
| Q1 24 | 12.3% | 4.0% |
每股收益（稀释后）PIPRRVTY
| Q4 25 | $6.41 | $0.86 | ||
| Q3 25 | $3.38 | $0.40 | ||
| Q2 25 | $2.38 | $0.46 | ||
| Q1 25 | $3.65 | $0.35 | ||
| Q4 24 | $3.88 | $0.77 | ||
| Q3 24 | $1.96 | $0.77 | ||
| Q2 24 | $1.97 | $0.45 | ||
| Q1 24 | $2.43 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.4B | $7.3B |
| 总资产 | $2.6B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PIPRRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $1.7B |
股东权益PIPRRVTY
| Q4 25 | $1.4B | $7.3B | ||
| Q3 25 | $1.3B | $7.4B | ||
| Q2 25 | $1.2B | $7.6B | ||
| Q1 25 | $1.2B | $7.6B | ||
| Q4 24 | $1.2B | $7.7B | ||
| Q3 24 | $1.2B | $7.9B | ||
| Q2 24 | $1.1B | $7.9B | ||
| Q1 24 | $1.1B | $7.8B |
总资产PIPRRVTY
| Q4 25 | $2.6B | $12.2B | ||
| Q3 25 | $2.2B | $12.1B | ||
| Q2 25 | $2.0B | $12.4B | ||
| Q1 25 | $1.8B | $12.4B | ||
| Q4 24 | $2.3B | $12.4B | ||
| Q3 24 | $2.0B | $12.8B | ||
| Q2 24 | $1.9B | $13.4B | ||
| Q1 24 | $1.8B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $729.8M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | 6.40× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流PIPRRVTY
| Q4 25 | $729.8M | $182.0M | ||
| Q3 25 | $31.9M | $138.5M | ||
| Q2 25 | $32.1M | $134.3M | ||
| Q1 25 | $-207.2M | $128.2M | ||
| Q4 24 | $163.8M | $174.2M | ||
| Q3 24 | $80.1M | $147.9M | ||
| Q2 24 | $266.5M | $158.6M | ||
| Q1 24 | $-197.2M | $147.6M |
自由现金流PIPRRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率PIPRRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度PIPRRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率PIPRRVTY
| Q4 25 | 6.40× | 1.85× | ||
| Q3 25 | 0.53× | 2.97× | ||
| Q2 25 | 0.76× | 2.49× | ||
| Q1 25 | -3.19× | 3.03× | ||
| Q4 24 | 2.37× | 1.84× | ||
| Q3 24 | 2.30× | 1.57× | ||
| Q2 24 | 7.66× | 2.87× | ||
| Q1 24 | -4.64× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PIPR
| Advisory Services | $402.6M | 60% |
| Equities Financing | $66.7M | 10% |
| Equity Salesand Trading | $64.2M | 10% |
| Fixed Income Salesand Trading | $47.9M | 7% |
| Other | $46.7M | 7% |
| Debt Financing | $38.9M | 6% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
